Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization.

Bone Marrow Transplantation
Luciano J CostaRobert K Stuart

Abstract

The ideal method to mobilize autologous hematopoietic stem cells (AHSCs) in patients with lymphoma or multiple myeloma remains to be determined. The use of plerixafor, added to growth factor, may overcome the limitations to the use of growth factor mobilization without chemotherapy. We developed and validated a cost-based decision-making algorithm that uses the CD34+ cell count in the peripheral blood on the fourth day of G-CSF administration and the target CD34+ cell count for the specific patient to decide on the use of plerixafor (MUSC algorithm). We compared this approach (MA cohort) with a historical cohort of patients undergoing mobilization with CY 2000 mg/m(2) followed by G-CSF and GM-CSF (CY cohort). Fifty individuals are included in the MA cohort and 81 in the CY cohort. The mobilization failure rate was 2% in the MA cohort vs 22% in the CY cohort (P=0.01). Fewer patients in the MA cohort than in the CY cohort had infectious complications during mobilization requiring hospitalization (2 vs 30% P<0.01). There was significant shortening in the median number of days between starting mobilization and undergoing transplantation in the MA cohort (14 vs 43 days, P<0.01). In conclusion, growth factor and patient-adapted use o...Continue Reading

References

Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K R DesikanG Tricot
Mar 29, 2002·The Hematology Journal : the Official Journal of the European Haematology Association·I N MicallefT A Lister
May 9, 2003·The New England Journal of Medicine·J Anthony ChildUNKNOWN Medical Research Council Adult Leukaemia Working Party
Oct 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harry C SchoutenGunnar Kvalheim
Mar 23, 2004·Bone Marrow Transplantation·T KuittinenE Jantunen
Jan 13, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Douglas A StewartGary Calandra
Jan 27, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Patrick StiffGary Calandra
May 20, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Uday PopatSergio Giralt

❮ Previous
Next ❯

Citations

Aug 30, 2011·Bone Marrow Transplantation·Ş M Bakanay, T Demirer
Nov 21, 2012·Bone Marrow Transplantation·W A WoodT C Shea
Nov 22, 2012·Mediterranean Journal of Hematology and Infectious Diseases·Roberto M Lemoli
Aug 3, 2011·Expert Opinion on Biological Therapy·Esa Jantunen
Oct 17, 2012·Blood Reviews·Ibraheem H Motabi, John F DiPersio
May 23, 2012·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Emre TekgündüzOsman Ilhan
Sep 17, 2011·Pathology·L Bik ToIan D Lewis
Oct 25, 2011·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·F BijouF Nicolini
Aug 13, 2011·Internal Medicine Journal·K E HerbertL B To
Oct 11, 2011·Transfusion·Esa Jantunen, Roberto M Lemoli
Apr 28, 2012·European Journal of Haematology·Ville VarmavuoEsa Jantunen
Mar 20, 2015·Journal of Clinical Apheresis·Sinem Civriz BozdagFevzi Altuntas
Jan 21, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Dawn SheppardJason Tay
Aug 16, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Steven M Devine
May 21, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Paul ShaughnessySimon Pickard
Oct 22, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sergio GiraltSteven Devine
Nov 12, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Luciano J CostaShaji Kumar
Jun 2, 2016·Clinical Lymphoma, Myeloma & Leukemia·Dennis L CooperYanyun Wu
Jun 28, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Binod DhakalMehdi Hamadani
Aug 20, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Hien D Liu
Dec 17, 2016·Revista da Associação Médica Brasileira·Fernando Barroso DuarteLuciano J Costa
Feb 12, 2020·JCO Oncology Practice·Ricardo D ParrondoVivek Roy
Dec 17, 2014·Cancer Control : Journal of the Moffitt Cancer Center·Luciano J CostaShari J Dermer
May 25, 2020·Bone Marrow Transplantation·Zoé Van de WyngaertUNKNOWN IFM (Intergroupe Français du Myélome – IFM 2014-05)
Mar 13, 2021·Journal of Clinical Apheresis·Srinivasa Reddy SanikommuBelinda R Avalos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.